Condition: Gastric Cancer · Gastroesophageal Junction Cancer · Sponsor: Daiichi Sankyo
This clinical trial is designed to assess the efficacy and safety of the triplet combination of trastuzumab deruxtecan (ENHERTU, T-DXd, DS-8201a) plus a fluoropyrimidine plus pembrolizumab versus standard of care (SoC) chemotherapy plus trastuzumab plus pembrolizumab as first-line therapy in participants with unresectable, locally advanced or metastatic HER2-positive tumor PD-L1 CPS ≥1 gastric or GEJ cancer in the Main Cohort. An Exploratory Cohort will also be evaluated to assess the efficacy and safety of T-DXd plus a fluoropyrimidine versus SoC chemotherapy plus trastuzumab in participants with unresectable, locally advanced or metastatic HER2-positive tumor PD-L1 CPS \<1 gastric or GEJ cancer.
This description comes directly from the study's public registry record.
Contact for Trial Information · 908-992-6400 · CTRinfo_us@daiichisankyo.com
Always discuss trial participation with your own doctor first.
| Yale Cancer Center | New Haven, Connecticut, United States | Not Yet Recruiting |
| Orchard Healthcare Research Inc. | Skokie, Illinois, United States | Recruiting |
| University of Kansas Medical Center Research Institute, Inc. | Kansas City, Kansas, United States | Not Yet Recruiting |
| Maryland Oncology Hematology, P.A. | Silver Spring, Maryland, United States | Not Yet Recruiting |
| Tufts Medical Center | Boston, Massachusetts, United States | Recruiting |
| University of Michigan Comprehensive Cancer Center Michigan Medicine | Ann Arbor, Michigan, United States | Recruiting |
| Minnesota Oncology Hematology, P.A. | Minneapolis, Minnesota, United States | Withdrawn |
| Memorial Sloan Kettering Cancer Center - MAIN | New York, New York, United States | Recruiting |
| Montefiore Medical Center | The Bronx, New York, United States | Recruiting |
| Providence Portland Medical Center | Portland, Oregon, United States | Recruiting |
| Penn State University Milton S. Hershey Medical Center | Hershey, Pennsylvania, United States | Recruiting |
| Prisma Health Cancer Institute, ITOR, CRU | Greenville, South Carolina, United States | Not Yet Recruiting |
+ 238 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06731478